Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pulse Pressure and Post-epidural Fetal Heart Rate Changes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02565485
Recruitment Status : Completed
First Posted : October 1, 2015
Results First Posted : June 8, 2018
Last Update Posted : July 9, 2018
Sponsor:
Information provided by (Responsible Party):
Edward Chien, MD, MetroHealth Medical Center

Brief Summary:
Epidural anesthesia, the most common method of pain control in labor, can contribute to alterations in maternal blood pressure and/or fetal heart rate changes. As a result, the administration of an IV fluid bolus ("preload") is standard prior to epidural placement. However, the optimal volume of preload is unknown and no clinical trials have evaluated a risk-factor based approach to dosing. Studies in the critical care, trauma, and obstetric literature have suggested that a narrow pulse pressure (difference between systolic and diastolic blood pressures) is a marker of reduced intravascular volume status and may identify women at a higher risk for new onset fetal heart rate changes after epidural placement. Therefore, the purpose of this study is to assess if an increased IV fluid preload bolus among women with a narrow pulse pressure reduces the risk of new onset fetal heart rate changes after epidural placement.

Condition or disease Intervention/treatment Phase
Fetus or Neonate Affected by Maternal Epidural Anesthesia During Labor and Delivery Drug: Lactated Ringer's Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 276 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Pulse Pressure-guided IV Fluid Preload to Prevent Post-epidural Fetal Heart Rate (FHR) Changes: a Randomized Controlled Trial
Actual Study Start Date : September 1, 2015
Actual Primary Completion Date : November 1, 2016
Actual Study Completion Date : November 1, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: Standard IV Preload
Patients in this arm will receive 500mL of Lactated Ringer's solution, which is the standard IV fluid preload used on Labor and Delivery at MetroHealth Medical Center
Experimental: Volume Replacement IV Preload
Patients in this arm will receive 1500mL of Lactated Ringer's solution
Drug: Lactated Ringer's
1500 cc of IV Fluid (crystalloid) used for preload prior to epidural administration in the treatment arm. Control arm receives 500 cc.
Other Name: Ringer's Lactate




Primary Outcome Measures :
  1. Incidence of New-onset Category II or III Fetal Heart Rate Tracings [ Time Frame: First 60 minutes following epidural placement ]
    Each fetal heart rate tracing was evaluated in 15 min increments from the completion of epidural placement and initial dose administration. ACOG Category I, II, and III was assigned to each 15 min increment.


Secondary Outcome Measures :
  1. New Onset Hypotension (>20% Decrease in Systolic and/or Diastolic Blood Pressure) [ Time Frame: First 60 minutes following epidural placement ]
  2. Interventions to Correct Maternal Hypotension or Fetal Heart Rate Abnormalities (Position Change, Supplemental Oxygen, Vasopressor Support, Emergent Operative Delivery) [ Time Frame: First 60 minutes following epidural placement ]
  3. Adverse Events (Pulmonary Edema) [ Time Frame: Duration of intrapartum course ]
    Pulmonary edema occurring after preload bolus through delivery was considered an adverse event.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Singleton pregnancy with gestational age ≥ 35 weeks
  • Admission for delivery
  • Age 18 or older
  • Desires neuraxial analgesia in labor
  • No exclusion criteria
  • Maternal pulse pressure < 45 mmHg on admission (verified by repeat blood pressure)
  • Category 1 FHT on admission/prior to epidural placement
  • Epidural placement within 6 hours of admission to Labor and Delivery

Exclusion Criteria:

  • Multiple gestation
  • Intrauterine growth restriction
  • Hypertensive disorders (gestational hypertension, chronic hypertension, and preeclampsia/eclampsia)
  • Gestational or pregestational diabetes mellitus
  • Substance abuse
  • Intrauterine fetal demise
  • Congenital or chromosomal fetal abnormalities
  • Category II or III FHR tracing on admission to L&D (pre-epidural)
  • Contraindication to neuraxial aesthesia (e.g. thrombocytopenia)
  • Maternal cardiomyopathy, congenital heart disease, active pulmonary edema or any other underlying maternal cardiopulmonary condition that increases the risk of pulmonary edema
  • Maternal renal insufficiency (serum creatinine > 1.0)
  • Maternal hypotension (as defined in secondary outcomes below) prior to epidural placement

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02565485


Locations
Layout table for location information
United States, Ohio
MetroHealth Medical Center
Cleveland, Ohio, United States, 44109
Sponsors and Collaborators
MetroHealth Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Justin R Lappen, MD MetroHealth Medical Center
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Edward Chien, MD, Professor, Reproductive Biology, MetroHealth Medical Center
ClinicalTrials.gov Identifier: NCT02565485    
Other Study ID Numbers: IRB15-00366
First Posted: October 1, 2015    Key Record Dates
Results First Posted: June 8, 2018
Last Update Posted: July 9, 2018
Last Verified: June 2018
Keywords provided by Edward Chien, MD, MetroHealth Medical Center:
pulse pressure
fetal heart rate
epidural analgesia
hypotension
preload
fluid bolus
central hypovolemia